Diagnosis: Mixed Obstructive-Restrictive Pattern with Significant Bronchodilator Response
This patient has a mixed ventilatory defect with substantial bronchodilator reversibility, most consistent with asthma-COPD overlap (ACO) or severe asthma with a restrictive component, rather than pure COPD.
Spirometric Interpretation
The pulmonary function tests reveal several critical findings:
- Pre-bronchodilator: FEV1/FVC ratio of 68% indicates airflow obstruction (below the 70% threshold) 1
- Both FEV1 (48%) and FVC (53%) are severely reduced, suggesting a mixed pattern rather than pure obstruction 2
- Post-bronchodilator FEV1 improves to 66% - this represents an 18% absolute improvement, which is highly significant reversibility (>12% and >200mL improvement defines reversibility) 3, 4
- DLCO of 117% is supranormal, which argues strongly against emphysematous COPD where DLCO would be reduced
Why This is NOT Typical COPD
The elevated DLCO is the key distinguishing feature. In COPD, particularly emphysema, DLCO is characteristically reduced due to alveolar destruction. A supranormal DLCO suggests:
- Increased pulmonary blood volume (asthma with airway inflammation)
- Absence of parenchymal destruction
- Possible obesity or polycythemia contributing to the pattern
The marked bronchodilator response (FEV1 improving from 48% to 66%) exceeds typical COPD reversibility and strongly suggests an asthmatic component 3, 4.
Likely Diagnosis: Asthma-COPD Overlap (ACO)
For patients displaying features of both asthma (significant reversibility, normal/elevated DLCO) and COPD (persistent baseline obstruction, reduced FEV1/FVC post-bronchodilator), ACO is the appropriate clinical descriptor 5. The restrictive component (low FVC) may reflect:
- Air trapping from severe airflow obstruction
- Obesity
- Coexisting restrictive lung disease
- Poor effort (though post-bronchodilator improvement argues against this)
Management Recommendations
Treatment should primarily follow asthma guidelines with ICS-based therapy as the foundation 3:
Initial Pharmacotherapy
- Start with ICS + LABA combination as first-line therapy 5
- This patient meets criteria for ACO treatment: significant reversibility, persistent obstruction, and severe airflow limitation (FEV1 <50% pre-bronchodilator)
- European guidelines uniformly recommend ICS + LABA for ACO patients 5
If Symptoms Persist
- Add LAMA (triple therapy: ICS + LABA + LAMA) 5
- Indicated for persistent breathlessness despite ICS + LABA
- Recommended for severe airflow obstruction (FEV1 <50%) with ongoing symptoms 5
Additional Considerations
- Assess exacerbation history: If ≥2 exacerbations per year, this further supports ICS use 5
- Smoking cessation if applicable (critical for preventing progression)
- Pulmonary rehabilitation for severe airflow limitation 5
- Consider systemic corticosteroid trial if diagnostic uncertainty remains - a positive response (≥10% improvement in FEV1 % predicted) would further support the asthmatic component 2
Critical Pitfalls to Avoid
- Do not treat as pure COPD with LAMA monotherapy - the significant reversibility and normal DLCO mandate ICS-based therapy to prevent exacerbations and disease progression
- Do not dismiss the restrictive component - investigate for obesity, interstitial lung disease, or neuromuscular causes if FVC remains low despite optimal bronchodilator therapy
- Monitor for ICS-related pneumonia risk 5, though this risk is outweighed by benefits in patients with significant reversibility
- Repeat spirometry after 3-6 months of treatment to assess response and confirm the diagnosis 6
The combination of severe airflow limitation with marked reversibility and preserved gas exchange distinguishes this from typical COPD and necessitates aggressive anti-inflammatory therapy with ICS as the cornerstone of management.